AAAAAA

   
Results: 1-16 |
Results: 16
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment
Authors: Wagner, U Kohler, S Reinartz, S Giffels, P Huober, J Renke, K Schlebusch, H Biersack, HJ Mobus, V Kreienberg, R Bauknecht, T Krebs, D Wallwiener, D
Citation: U. Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment, CLIN CANC R, 7(5), 2001, pp. 1154-1162
Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer
Authors: Ulrich, U Rhiem, K Schmolling, J Flaskamp, C Paffenholz, I Salzer, H Bauknecht, T Schlebusch, H
Citation: U. Ulrich et al., Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer, ARCH GYN OB, 264(4), 2001, pp. 186-190
Evaluation of methods to detect p53 mutations in ovarian cancer
Authors: Meinhold-Heerlein, I Ninci, E Ikenberg, H Brandstetter, T Ihling, C Schwenk, I Straub, A Schmitt, B Bettendorf, H Iggo, R Bauknecht, T
Citation: I. Meinhold-heerlein et al., Evaluation of methods to detect p53 mutations in ovarian cancer, ONCOL-BASEL, 60(2), 2001, pp. 176-188
Granulocyte colony-stimulating factor (G-CSF) receptor gene expression of ovarian carcinoma does not correlate with G-CSF caused cell proliferation
Authors: Brandstetter, T Ninci, E Bettendorf, H Perewusnyk, G Stolte, J Herchenbach, D Sellin, D Wagner, E Kochli, OR Bauknecht, T
Citation: T. Brandstetter et al., Granulocyte colony-stimulating factor (G-CSF) receptor gene expression of ovarian carcinoma does not correlate with G-CSF caused cell proliferation, CANCER, 91(7), 2001, pp. 1372-1383
Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer
Authors: Meinhold-Heerlein, I Stenner-Liewen, F Liewen, H Kitada, S Krajewska, M Krajewski, S Zapata, JM Monks, A Scudiero, DA Bauknecht, T Reed, JC
Citation: I. Meinhold-heerlein et al., Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer, AM J PATH, 158(4), 2001, pp. 1335-1344
Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
Authors: Ressing, ME van Driel, WJ Brandt, RMP Kenter, GG de Jong, JH Bauknecht, T Fleuren, GJ Hoogerhout, P Offringa, R Sette, A Celis, E Grey, H Trimbos, BJ Kast, WM Melief, CJM
Citation: Me. Ressing et al., Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma, J IMMUNOTH, 23(2), 2000, pp. 255-266
G-CSF receptor expression in ovarian cancer
Authors: Ninci, EB Brandstetter, T Meinhold-Heerlein, I Bettendorf, H Sellin, D Bauknecht, T
Citation: Eb. Ninci et al., G-CSF receptor expression in ovarian cancer, INT J GYN C, 10(1), 2000, pp. 19-26
Caelyx (R) in the treatment of advanced ovarian cancer
Authors: Bauknecht, T
Citation: T. Bauknecht, Caelyx (R) in the treatment of advanced ovarian cancer, ONKOLOGIE, 23, 2000, pp. 40-45
Second-line chemotherapie after platinum or platinum and paclitaxel-based chemotherapy for ovarian cancer: A systematic review
Authors: du Bois, A Luck, HJ Bauknecht, T Pfisterer, J Meier, W
Citation: A. Du Bois et al., Second-line chemotherapie after platinum or platinum and paclitaxel-based chemotherapy for ovarian cancer: A systematic review, GEBURTSH FR, 60(1), 2000, pp. 41-58
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial
Authors: van Driel, WJ Ressing, ME Kenter, GG Brandt, RMP Krul, EJT van Rossum, AB Schuuring, E Offringa, R Bauknecht, T Tamm-Hermelink, A van Dam, PA Fleuren, GJ Kast, WM Melief, CJM Trimbos, JB
Citation: Wj. Van Driel et al., Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial, EUR J CANC, 35(6), 1999, pp. 946-952
Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy
Authors: du Bois, A Schlaich, M Luck, HJ Mollenkopf, A Wechsel, U Rauchholz, M Bauknecht, T Meerpohl, HG
Citation: A. Du Bois et al., Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy, SUPP CARE C, 7(5), 1999, pp. 354-361
Phase II study of gemcitabine in ovarian cancer
Authors: von Minckwitz, G Bauknecht, T Visseren-Grul, CM Neijt, JP
Citation: G. Von Minckwitz et al., Phase II study of gemcitabine in ovarian cancer, ANN ONCOL, 10(7), 1999, pp. 853-855
First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: A phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group
Authors: du Bois, A Luck, HJ Bauknecht, T Meier, W Richter, B Kuhn, W Quaas, J Pfisterer, J
Citation: A. Du Bois et al., First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: A phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group, J CL ONCOL, 17(1), 1999, pp. 46-51
First-line chemotherapy in advanced ovarian cancer: State of the art and future aspects
Authors: du Bois, A Luck, HJ Bauknecht, T
Citation: A. Du Bois et al., First-line chemotherapy in advanced ovarian cancer: State of the art and future aspects, ONKOLOGIE, 22(4), 1999, pp. 269-280
Gene therapy approaches in gynecological oncology
Authors: Bauknecht, T
Citation: T. Bauknecht, Gene therapy approaches in gynecological oncology, ONKOLOGIE, 22, 1999, pp. 31-32
Response to IL-6 of HPV-18 cervical carcinoma cell lines
Authors: Bauknecht, T Randelzhofer, B Schmitt, B Ban, Z Hernando, JJ Bauknecht, T
Citation: T. Bauknecht et al., Response to IL-6 of HPV-18 cervical carcinoma cell lines, VIROLOGY, 258(2), 1999, pp. 344-354
Risultati: 1-16 |